Alaunos Therapeutics, Inc. (TCRT) Form 8-K — Oct 13, 2026
$TCRTForm 8-KItems 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01Filed Oct 13, 2026, 9:28 AM ET0001193125-26-419829Original filing
Alaunos Therapeutics (TCRT) completed its merger with Velaris Therapeutics on October 13, 2026, issuing 105,286 Series B and 33,054 Series C non-voting convertible preferred shares (each convertible into 1,000 common shares) to Velaris holders, with the deal based on a $200 million Velaris valuation versus only $15 million for Alaunos. Concurrently, Alaunos signed a ~$350 million PIPE (687,789 common shares at $1.4357 and 243,063 Series C preferred at $1,435.70), with Fairmount-affiliated funds committing ~$100 million as Lead Investor.
Key figures
- Deal Value Usd
- 200000000
- Gross Proceeds
- 350000000
- Offering Price
- $1.4357 per common share; $1,435.70 per Series C preferred share
- Shares Offered
- 687,789 common shares and 243,063 Series C preferred shares
- Exchange ratio
- 5.2643
- Lockup period days
- 180
- Retention bonus ceo
- $206,250
- Parent valuation usd
- 15000000
- Series b shares issued
- 105286
- Fairmount pipe commitment
- approximately $100.0 million
- Conversion ratio preferred
- 1 preferred share = 1,000 common shares
- Retention bonus vp finance
- $90,000
- Preferred repurchase amount
- approximately $1.6 million
- Series c shares issued merger
- 33054
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.